Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Pacira_BioSciences
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:CEO |
Michael Clayman
|
| gptkbp:focusesOn |
musculoskeletal conditions
|
| gptkbp:foundedIn |
2007
|
| gptkbp:founder |
Michael Clayman
Neil Bodick |
| gptkbp:headquartersLocation |
gptkb:Burlington,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Flexion Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
Zilretta
|
| gptkbp:numberOfEmployees |
approximately 200 (2021)
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:status |
gptkb:subsidiary
|
| gptkbp:stockSymbol |
FLXN
|
| gptkbp:website |
https://www.flexiontherapeutics.com/
|
| gptkbp:ZilrettaIndication |
osteoarthritis knee pain
|
| gptkbp:bfsParent |
gptkb:Pacira_BioSciences
|
| gptkbp:bfsLayer |
8
|